Background: Considering the relationship between inflammation and thrombosis, patients with tuberculosis (TB) patients might be at high risk of venous thrombosis. Aim: To evaluate the risk of venous thromboembolism in patients admitted to the Beatrixoord Tuberculosis Centre (BTBC), a tertiary centre for TB. We specifically explored which cofactors elevate the risk of venous thrombosis (VTE), and whether the timing of venous thrombotic events would justify extended primary prophylaxis. Design: retrospective cohort study. Methods: We performed a retrospective chart review of all patients with TB discharged from BTBC between 2000 and 2010. We excluded patients who were already on therapeutic anticoagulation before their TB episode, below the age of 18 years and patients in which TB diagnosis was withdrawn. For evaluating the timing of venous thrombosis, we calculated the time between commencement of anti TB therapy and the VTE. Results: Of 750 included in the final analysis, 18 (2.4%) suffered a venous thrombotic event. 3 of these events were not related to classic risk factors or hospitalization. Most (13/18) VTE's occurred in the time window of two weeks before starting TB medication. In the multivariate analysis, only Human Immunodeficiency Virus (HIV) infection was strongly associated with risk of VTE (adjusted Odds ratio 8.2 (95% confidence interval: 2.9-22.7)). Conclusions: This high risk in HIV co-infected TB patients suggests that standard thrombo-prophylaxis should be routinely considered in this group. However, our findings might not be generalizable due to referral bias. Further prospective studies in unselected HIV co-infected TB patients are needed to corroborate our findings.
Introduction
Infectious and inflammatory diseases increase the risk of venous thromboembolic events (VTE). 1, 2 The risk of VTE increases on par with inflammatory activity of the underlying condition. 3 Considering these findings, patients with tuberculosis (TB) may be at a particularly high risk of VTE, for two reasons. First, as an infectious disease, the clinical course of TB is characterized by diagnostic delays and slow resolution of symptoms when compared to acute infections. 4, 5 Thus, the overall exposure to inflammation is longer than in acute infections. Second, TB is frequently associated with other (chronic) infections, such as Human Immunodeficiency Virus (HIV) infection and viral hepatitis, meaning patients with TB frequently have a double, perhaps even triple inflammatory burden. These two factors may elevate the risk of VTE significantly. If this absolute risk is high enough, there might be an indication to intensify and/or extend pharmacological thrombo-prophylaxis. We therefore studied the risk of VTE in patients admitted for TB to Beatrixoord TB Centre (BTBC), Groningen, the Netherlands. We specifically aimed to explore the timing of diagnosis of VTE, the impact of TB disease severity on VTE and whether co-infections have an additive effect on the risk of VTE.
Methods
In this retrospective cohort study, one author (JFB) reviewed all charts of TB patients discharged (alive or deceased) after a first admission to BTBC, Groningen, the Netherlands, from the years 2000 through 2010. The case mix of TB patients mostly comprised patients who had a relatively stable somatic condition but needed inpatient care because of psychosocial factors, and patients who had severe debilitating TB with comorbidities requiring long-term inpatient care.
Patients included in this analysis either had microbiologically confirmed infection with Mycobacterium tuberculosis complex or had their diagnosis based on clinical grounds with initiation of anti-TB chemotherapy for at least six months. We excluded patients below age 18 years as well as those already on chronic therapeutic anticoagulant therapy (vitamin K antagonists or low molecular weight heparin) before their TB episode. We only analysed patients with a first admission to BTBC. This means that we excluded patients who were re-admitted for a second episode of TB (either endogenous reactivation or re-infection), but did not exclude observations made in a readmission for the same episode of TB. See also Figure 1 .
Primary outcome was VTE, with no restriction on localization. A VTE event was defined as confirmed if relevant imaging (i.e. ultrasound, computerized tomography or ventilation-perfusion scintigraphy) was recorded (we did not demand availability of a radiology report), or if VTE-related anticoagulant therapy was administered for at least 3 months to patients in whom detailed reports of imaging were not present in BTBC charts. Considering the average diagnostic delay reported in TB, 5 a VTE was assumed to be related to TB if it occurred in the period between three months before the date in which anti-TB chemotherapy was started 'and' day of discharge from BTBC. The date of VTE diagnosis was recorded and any relevant exposure (up to 6 weeks before VTE) to classic risk factors for venous thrombosis, including surgery, pregnancy, malignancy, immobilization, use of oral contraceptives and hospitalization. Likewise for patients without a VTE, any exposure to classic risk factors and hospitalization was recorded in the 3 months before starting TB treatment and discharge from BTBC. Considering that the majority of patients admitted to BTBC are ambulatory, patients were only defined as hospitalized if they had been admitted to a hospital elsewhere before referral to 'or' during their stay at BTBC. Patients were defined as immobilized if they had a plaster cast, a fracture or paralysis of a lower extremity or if they had clearly been bedridden for over 3 days. Time relationships between VTE and TB were evaluated by calculating the weeks between diagnosis of VTE and commencement of treatment for TB. We considered using the date in which the first microbiological culture was sent for analysis as time marker, but we found that these dates were frequently missing in available charts.
We evaluated TB organ involvement as an estimate TB disease severity. Patients were defined as having pulmonary TB or extra pulmonary TB according to the world health organisation (WHO) reporting framework. 6 Patients who had clinical signs of TB involvement in more than one organ were labelled as having disseminated TB. Organ involvement was based on clinical suspicion on relevant imaging or results of microbiological samples (microscopy, culture and polymerase chain reaction results). HIV status was defined through results of antibody testing. Patients with unknown serostatus were assumed to be seronegative. There were too many missing values to assess any association between co-infection with viral hepatitides and VTE.
Data were analysed using SPSS version 22 (IBM, Chicago, USA); Odds ratios (OR) as estimates of the risk of VTE were calculated manually by making contingency tables and by binary logistic regression, together with 95% confidence intervals (CI). Variables with a clear relationship to venous thrombosis (e.g. sex, classic risk factors) and variables with a P values lower than 0.10 in the univariate analysis were entered in the multivariate analysis.
Results
Out of 826 case records of unique patients, 76 were excluded, leaving 750 TB cases for the analysis of prevalence of VTE (see Figure 1 ). One patient died in circumstances suspicious of massive pulmonary embolism (thrombolysis was initiated) but neither diagnostic imaging nor autopsy was performed. This case was consequently excluded from the current analysis. Most patients in the cohort were male (n ¼ 522, 70%); median age was 35 years. Eighteen patients (2.4%) fulfilled the criteria for TBassociated VTE. Of these VTEs, 17 were diagnosed before admission to BTBC. The median age at VTE diagnosis was 42 years (range 21-57). Hospitalization was an associated risk factor in 14 of the 18 VTEs. Other classic risk factors were present in 5 of the 18 VTEs. This left three VTEs not associated with either hospitalization or classic risk factors, translating into a VTE risk of 1% in TB patients not exposed to hospitalization or classic risk factors.
In the univariate analysis (see Table 1 ), HIV co-infection, disseminated TB and exposure to any classic risk factor (including hospitalization) were significantly associated with a P values below 0.10. These values and male sex were included in the multivariate analysis, which showed that only HIV co-infection was independently associated with VTE (OR 8.2, 95% CI 2.9-22.7).
The median time between diagnosis of VTE and day of commencing anti-TB chemotherapy was 0 week (range 6 weeks before starting chemotherapy to 26 weeks after starting chemotherapy). Of these VTEs, five occurred late (>2 weeks) after starting anti-TB chemotherapy; three of these were very late (>20 weeks after commencement of treatment). Two of these very late VTEs were associated with TB treatment failure. The third very late VTE occurred in a patient during puerperium who was still being treated for multidrug resistant TB.
Discussion
In this cohort of TB patients, 2.4% of patients had a VTE. In most patients (83%), this was related to provoking factors. In patients not exposed to provoking factors, the risk of VTE was 1%. Given a 'yearly' incidence of VTE of 0.16% in the general population, 7 our results further strengthen the notion that TB is an independent risk factor for VTE. However, we could not statistically test this, as it was not possible to calculate time-dependent incidence in our cohort. Indeed, considering inevitable patient/doctor/diagnostic delay, it would be challenging to universally define the exact relevant observation period to evaluate timedependent VTE risk in TB patients. Other data supporting the notion that TB is a relevant risk factor for VTE were recently reported by Govender et al., 8 showing that in HIV-infected patients 7.4% developed a VTE with 47% of these having TB as co-infection, and by Dentan et al., 9 who showed a VTE rate of 2.07% in TB patients. Of note, in that study TB was associated with a relative risk of VTE of the same order of magnitude as cancer, a well-established independent risk factor for VTE. The main difference between the current study and the one by Dentan et al.
was that the latter restricted to VTEs occurring during hospitalization. In our subgroup of hospitalized patients, we found a slightly higher risk of VTE (3.2%).
In the current analysis, patients with HIV co-infection and disseminated TB had the highest risk of developing a VTE. Disseminated TB was not a significant risk factor in the multivariate analysis-probably due to confounding by HIV infection, which is a risk factor for VTE as well as dissemination of TB infection to multiple organs due to the decreased cellular immunity. Interestingly, HIV co-infection was not evaluated as a risk factor for VTE in the study by Dentan et al., 9 nor in other studies evaluating the association between TB-associated VTE risk that we are aware of. 10, 11 The high risk of VTE (>5%) in TB patients with an HIV co-infection may warrant the use of intensive and/ or extended medical thrombo-prophylaxis in these patients, as this risk mirrors the rate seen in multiple myeloma-a disease for which extended thrombo-prophylaxis during active disease/ treatment is recommended. 12, 13 Conversely, our 'overall' findings challenge whether standard initiation of extended thrombo-prophylaxis (i.e. duration > 6 weeks) would be an effective thrombo-prophylaxis strategy, considering the fact that most of the patients (14/18) in this cohort were diagnosed with a VTE before or close to the time that anti-TB chemotherapy was started. In other words: not much of the TB attributable risk remained to be prevented by starting thrombo-prophylaxis after the initial phase of TB treatment. However, in selected patients (i.e. those with an HIV co-infection or a classic VTE risk factor) thrombo-prophylaxis might be considered, perhaps by intensification of thrombo-prophylaxis.
The main limitation of our study may be that absolute risks are overestimated due to referral bias, as our centre is a tertiary centre. However, social (and not medical) complexity was the most common reason for referral. So the traditional concept of referral bias (sicker patients are referred and therefore generally at higher risk of complications) is probably not applicable to this cohort. To resolve this issue, these findings should be confirmed in studies in unselected patients suffering from HIV/TB co-infection, as they may have consequences for preventing VTE related morbidity and mortality for a potentially large amount of patients worldwide. Given the estimated burden of TB in HIV-related mortality, 14 it should be feasible to collect prospective data on the risk of VTE in patients co-infected with HIV and TB. VTE, venous thromboembolic events; TB, tuberculosis; RF, risk factor; þve, positive; Àve, negative; OR, odds ratio; CI, confidence interval; aOR, adjusted odds ratio.
